Westfield Capital (NASDAQ: ASND) reports 8.48% passive Ascendis stake

Rhea-AI Filing Summary

Ascendis Pharma A/S received an amended ownership report showing that Westfield Capital Management Company, L.P. beneficially owns 5,185,696 shares of Ascendis common stock, representing 8.48% of the class as of 12/31/2025.

Westfield has sole power to vote 4,244,766 shares and sole power to dispose of 5,185,696 shares. The shares are owned of record by Westfield’s investment advisory clients, who receive dividends and sale proceeds. Westfield states the holdings are in the ordinary course of business and not for influencing control.

Insights

Equity ownership & governance analyst

Westfield reports an 8.48% passive stake in Ascendis Pharma on behalf of clients.

Westfield Capital Management Company, L.P. reports beneficial ownership of 5,185,696 Ascendis Pharma common shares, equal to 8.48% of the class as of December 31, 2025. It holds sole voting power over 4,244,766 shares and sole dispositive power over the full 5,185,696.

The shares are owned of record by Westfield’s advisory clients, who are entitled to dividends and sale proceeds. Westfield indicates, to the best of its knowledge, that no single client has rights over more than five percent of the class.

Westfield certifies that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Ascendis Pharma, other than activities solely in connection with a nomination under Rule 240.14a-11. This characterizes the position as a passive institutional investment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Ascendis Pharma A/S

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04351P101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 04351P101

1

Names of Reporting Persons

Westfield Capital Management Company, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,244,766.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,185,696.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,185,696.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.48 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Ascendis Pharma A/S
(b)	Address of issuer's principal executive offices: TUBORG BOULEVARD 12, HELLERUP, DENMARK 00000
Item 2.
(a)	Name of person filing: Westfield Capital Management Company, L.P.
(b)	Address or principal business office or, if none, residence: 1 Financial Center, 24th Floor Boston, Massachusetts 02111
(c)	Citizenship: Westfield Capital Management Company, L.P. - MASSACHUSETTS
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 04351P101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5,185,696
(b)	Percent of class: 8.48 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Westfield Capital Management Company, L.P. - 4,244,766
	(ii) Shared power to vote or to direct the vote: Westfield Capital Management Company, L.P. - 0
	(iii) Sole power to dispose or to direct the disposition of: Westfield Capital Management Company, L.P. - 5,185,696
	(iv) Shared power to dispose or to direct the disposition of: Westfield Capital Management Company, L.P. - 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The shares of the security listed in this Schedule are owned of record by clients of Westfield Capital Management Company, L.P. (Westfield) in its capacity as investment adviser. Westfield's clients have the right to receive, or the power to direct the receipt of, dividends or proceeds from the sale of the shares. To the best of Westfield's knowledge, no client has such right or power with respect to more than five percent of this class of security.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Westfield Capital Management Company, L.P.

Signature:	/s/ Brandi McMahon
Name/Title:	Vice President, Deputy Chief Compliance Officer
Date:	02/10/2026

FAQ

What percentage of Ascendis Pharma (ASND) shares does Westfield Capital own?

Westfield Capital Management Company, L.P. reports beneficial ownership of 8.48% of Ascendis Pharma’s common stock. This corresponds to 5,185,696 shares as of December 31, 2025, giving it a significant but minority institutional position in the company.

How many Ascendis Pharma (ASND) shares can Westfield Capital vote and dispose of?

Westfield Capital has sole voting power over 4,244,766 Ascendis Pharma shares and sole power to dispose of 5,185,696 shares. It reports no shared voting or dispositive power, indicating centralized decision-making authority at the adviser level for this stake.

Are the Ascendis Pharma (ASND) shares held directly by Westfield Capital?

The Ascendis Pharma shares are owned of record by clients of Westfield Capital, not by Westfield itself. Westfield holds them in its capacity as investment adviser, while clients have rights to receive dividends and proceeds from any sale of the securities.

Does any Westfield Capital client hold more than 5% of Ascendis Pharma (ASND)?

Westfield states that, to the best of its knowledge, no individual client has the right to receive dividends or sale proceeds for more than 5% of Ascendis Pharma’s common stock. This suggests the 8.48% beneficial stake is spread across multiple advisory accounts.

Is Westfield Capital’s Ascendis Pharma (ASND) stake intended to influence control of the company?

Westfield certifies the securities were acquired and are held in the ordinary course of business and not to change or influence control of Ascendis Pharma. It disclaims control intent, except for activities solely in connection with a nomination under Rule 240.14a-11.

What type of SEC filing discloses Westfield Capital’s Ascendis Pharma (ASND) ownership?

Westfield’s ownership in Ascendis Pharma is reported on an amended Schedule 13G (Amendment No. 4). This form is typically used by investors who hold a significant stake but classify themselves as passive rather than seeking to influence corporate control.